Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfaf043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.
Circ J
March 2025
Kawasaki Geriatric Medical Center, Kawasaki Medical School.
Background: Patients with both heart failure (HF) and chronic kidney disease (CKD) are often treated with renin-angiotensin-aldosterone system inhibitors (RAASi), but these drugs can cause hyperkalemia, which may lead to their reduction or discontinuation, resulting in the loss of their beneficial effects. Approaches to managing RAASi-induced hyperkalemia are discordant, so in this study we aimed to establish a cross-specialty consensus on the optimal approach to managing hyperkalemia in patients with HF and CKD.
Methods And Results: The study used a modified Delphi methodology.
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cancer Treat Rev
March 2025
Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas Research Hospital, Via Rita Levi Montalcini, 4, 20072 Pieve Emanuele, Milan, Italy. Electronic address:
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional guidelines recommend first-line therapy with an immune checkpoint inhibitor (with or without chemotherapy) or a cetuximab-based regimen, by assessment of expression levels of the biomarker programmed cell death-ligand 1 (PD-L1). However, patient- and tumor-specific factors, including the patient's age, comorbidities, performance status, and tumor burden, kinetics and spread also need to be considered to optimize treatment in the first line.
View Article and Find Full Text PDFThe value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean?
Expert Rev Mol Diagn
March 2025
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
[Early conversion to belatacept post-transplantation: state of the art and expert opinion].
Nephrol Ther
March 2025
Néphrologie, hémodialyse, aphérèse et transplantation, CHU Grenoble Alpes, La Tronche, France
Article Synopsis
- The standard immunosuppressive regimen after organ transplantation typically includes drugs like tacrolimus, mycophenolic acid, and corticosteroids, which can cause side effects like kidney damage.
- Belatacept offers a promising alternative by blocking a key costimulation pathway, showing improved kidney function and reduced donor-specific antibodies in early studies, despite a higher risk of acute rejections.
- Research highlights the benefits of converting to belatacept within the first six months after kidney transplantation, while also emphasizing the need for careful monitoring of rejection and infection risks.
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.
Ann Intern Med
March 2025
Charité Universitätsmedizin Berlin, Berlin, Germany (E.S.).
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy.
Methods: The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!